论文部分内容阅读
急性髓细胞白血病(AML)是一组异质性疾病,传统上根据外周血和骨髓中原始细胞的最小数值来区分其他髓系肿瘤。虽然大多数AML都这样诊断,但是目前有几种特殊类型的AML可以不依据原始细胞的计数来诊断。根据WHO 2008造血系统疾病的分型规则,只要检出克隆性重现性细胞遗传学异常t(15;17)(q22;q11-12)PML/RARα和t(8;21)(q22;q22)AML1/ETO,即使原始细胞未达到20%,即可诊断为t(15;17)AML和t(8;21)AML。以慢性粒单核细胞白血病(CMML)样表现
Acute myeloid leukemia (AML) is a heterogeneous group of diseases that traditionally distinguish other myeloid tumors based on the smallest numbers of blasts in the peripheral blood and bone marrow. Although most AMLs are diagnosed this way, there are currently several special types of AML that can not be diagnosed based on the count of blasts. According to the classification rules of the WHO 2008 hematopoietic system diseases, clonality of reproducible cytogenetic abnormalities (15; 17) (q22; q11-12) can be detected only if PML / RARα and t (8; 21) (q22; q22 ) AML1 / ETO is diagnosed as t (15; 17) AML and t (8; 21) AML even though the original cells do not reach 20%. Chronic myeloid leukemia (CMML) -like performance